Navigating the Adverse Effects of ADT: Improving Patient Outcomes

Prostate cancer (PCa) is associated with the second highest number of cancer related deaths in men, second only to skin cancer. It is the most commonly diagnosed problem with the genitourinary tract and approximately one in six men will be diagnosed with PCa in his lifetime. According to the American Cancer Society, it is estimated that there will be 180,890 new cases of prostate cancer, and about 26,120 deaths from prostate cancer in 2016.


A major debate in the use of ADT is whether intermittent or continuous therapy is the best for prostate cancer patients. In a meta-analysis published in late 2015, data from 15 clinical trials that compared intermittent and continuous ADT and found no significant difference in overall survival, cancer-specific survival, PFS, and quality of life was slightly improved with intermittent ADT. Other studies and analyses argue that the differences do not merit a change from the standard treatment, rendering the use of intermittent ADT investigational. The contradictory results of different studies of continuous to intermittent ADT, this debate leaves the best course of action uncertain for now.  This educational program will equip urologists, medical oncologists, radiation oncologists, and other healthcare providers involved in the treatment of patients who might undergo or have undergone androgen deprivation therapy (ADT) with the up-to-date clinical knowledge and tools they need to best diagnose and treat their patients and adverse effects they may face.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical College of Wisconsin and (name of non-accredited provider). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation
The Medical College of Wisconsin designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, May 25, 2017 to May 25, 2018.

Target Audience

The intended audience for this activity is urologists, medical oncologists, radiation oncologists, and other healthcare providers involved in the treatment of patients who might undergo or have undergone androgen deprivation therapy (ADT).

Learning Objectives

  • Evaluate the recommendations for current use and mechanisms of actions of ADT options for prostate cancer treatment
  • Identify the effects of ADT on quality of life
  • Address the impact of ADT on bone loss and related side effects
  • Assess the research evidence showing cardiovascular and metabolic risks caused by ADT therapy in advanced prostate cancer patients
Additional information

Contact

Name: 
Garland Branch
Phone Number: 
+1 (434) 817-2000
Email: 
gtbranch@cjp.com
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.50 Hours of Participation
    Hours of Participation credit.
Course opens: 
05/25/2017
Course expires: 
05/25/2018
Cost:
$0.00

Faculty and Planner Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

E. David Crawford, MD discloses the following relevant financial relationships:
Served as a consultant or advisor for: Dendreon, Ferring, Genomic Health, Janssen, MDx
Served as a consultant or advisor, meeting participant or lecturer for: Bayer
Received grants for clinical research from: NIH, University of Colorado Cancer Center
His wife is an employee of Dendreon

Thomas E. Keane, MBBCh discloses the following relevant financial relationships:
Served as a consultant for: Bayer, Ferring, Janssen

Jehonathan H. Pinthus, MD, PhD discloses the following relevant financial relationship:
Served as a speaker for: Ferring

Neal D. Shore, MD discloses the following relevant financial relationships:
Served as a consultant for: Amgen, AbbVie, Astellas, Bayer, Dendreon, Ferring, Janssen, Medivation, Sanofi, Tolmar

The educational content of this program has been peer reviewed by The Medical College of Wisconsin. The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose. Signed disclosures are on file at The Medical College of Wisconsin.

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.50 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.